Overview

Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection

Status:
Approved for marketing
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is to assess VariZIG™ for the treatment of patients at risk for developing serious complications from chicken pox.
Details
Lead Sponsor:
Cangene Corporation
Treatments:
Antibodies
gamma-Globulins
Immune Sera
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin